A day after his company’s stock began broadly trading on exchanges in New York and Paris, AbbVie Inc., CEO Richard Gonzalez took to the road for the first time as head of the industry’s newest big pharma, arguing forcefully that his company will fare better as an independent entity than as the largest subsidiary of Abbott Laboratories Inc.
AbbVie’s activities will be more transparent to investors and it will be able to align its capital allocation plans with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?